51S Stock Overview
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.12 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.079 |
| Beta | 0.91 |
| 1 Month Change | -3.88% |
| 3 Month Change | -2.36% |
| 1 Year Change | 47.62% |
| 3 Year Change | -46.55% |
| 5 Year Change | -83.36% |
| Change since IPO | -58.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 51S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 1.0% | 2.0% |
| 1Y | 47.6% | -4.8% | 15.2% |
Return vs Industry: 51S exceeded the German Biotechs industry which returned -6.5% over the past year.
Return vs Market: 51S exceeded the German Market which returned 14.1% over the past year.
Price Volatility
| 51S volatility | |
|---|---|
| 51S Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 51S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 51S's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
Cynata Therapeutics Limited Fundamentals Summary
| 51S fundamental statistics | |
|---|---|
| Market cap | €28.94m |
| Earnings (TTM) | -€5.82m |
| Revenue (TTM) | €1.38m |
20.9x
P/S Ratio-5.0x
P/E RatioIs 51S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 51S income statement (TTM) | |
|---|---|
| Revenue | AU$2.32m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.32m |
| Other Expenses | AU$12.06m |
| Earnings | -AU$9.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | -0.043 |
| Gross Margin | 100.00% |
| Net Profit Margin | -420.82% |
| Debt/Equity Ratio | 0% |
How did 51S perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 13:22 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cynata Therapeutics Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Chris Kallos | MST Financial Services Pty Limited |
| Raghuram Selvaraju | Rodman & Renshaw, LLC |